Esophageal adenocarcinoma (EAC) is a highly lethal cancer, with a five-year survival rate of less than 20 percent. Although a precursor lesion to EAC, called Barrett’s esophagus (BE), is present in roughly seven percent of middle-aged adults, less than one percent of BE patients will progress to EAC, making it difficult to determine which individuals are at risk of developing this deadly cancer.
FDA raises cleaning and quality concerns at another Ipca Laboratories manufacturing site in India
Indian manufacturer Ipca Laboratories has another production site under the FDA’s microscope after an inspection revealed several quality issues. The FDA identified eight overarching issues
July 7, 2023